XML 28 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Share-based Compensation
6 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]
10.
SHARE-BASED COMPENSATION
 
The Company has share-based compensation plans, which are more fully described in Note
10,
Share-Based Compensation, to the Consolidated Financial Statements included in the Company's annual report on Form
10
-K for the fiscal year ended
March 31, 2020
as filed with the SEC on
June 23, 2020.
 
As of
September 
30,
2020,
the Company had
two
equity-based compensation plans: the
2016
Equity Incentive Plan (the
“2016
Plan”) and the
2014
Independent Director Stock Option and Restricted Stock Grant Plan (the
“2014
Directors Plan”). The Company has also issued stock options, which remain outstanding as of
September 30, 2020,
under
two
equity-based compensation plans which have expired according to their terms: the
2005
Stock Option Plan (the
“2005
Plan”) and the
2004
Independent Director Stock Option and Stock Grant Plan (the
“2004
Directors Plan”). These plans allowed the Company to award stock options and shares of restricted common stock to eligible employees, certain outside consultants and independent directors.
No
additional awards will be issued under the
2005
Plan or the
2004
Directors Plan. 
 
The following table presents shares authorized, available for future grant and outstanding under each of the Company's plans:
 
   
As of
September
3
0
, 20
20
 
   
Authorized
   
Available
   
Outstanding
 
                         
2016 Plan
   
1,300,000
     
1,065,358
     
176,688
 
2014 Directors Plan
   
350,000
     
43,133
     
12,000
 
2005 Plan
   
     
     
235,300
 
2004 Directors Plan
   
     
     
12,000
 
Total
   
1,650,000
     
1,108,491
     
435,988
 
 
Stock Options
 
All stock option grants made under the equity-based compensation plans were issued at exercise prices
no
less than the Company's closing stock price on the date of grant. Options under the
2016
Plan,
2005
Plan and
2014
Directors Plan were determined by the Board of Directors or the Compensation Committee of the Board of Directors in accordance with the provisions of the respective plans.  The terms of each option grant include vesting, exercise, and other conditions set forth in a Stock Option Agreement evidencing each grant.
No
option can have a life in excess of
ten
(
10
) years. The Company records compensation expense for employee stock options based on the estimated fair value of the options on the date of grant using the Black-Scholes option-pricing model. The model requires various assumptions, including a risk-free interest rate, the expected term of the options, the expected stock price volatility over the expected term of the options, and the expected dividend yield. Compensation expense for employee stock options is recognized ratably over the vesting term. Compensation expense recognized for options issued under all Plans was
$4,000
and
$5,000
for the
three
months ended
September 30, 2020
and
2019,
respectively. Compensation expense recognized for options issued under all Plans was
$8,000
and
$118,000
for the
six
months ended
September 30, 2020
and
2019,
respectively. In the
first
six
months of fiscal year
2020,
compensation expense included
$109,000
related to a settlement agreement with a former executive.
 
A summary of option activity under the Company's stock plans for the
six
months ended
September 30, 2020
is presented below: 
 
Option Activity
 
Shares
   
Weighted
Average
Exercise
Price
   
Weighted
Average
Remaining
Contractual
Term (in
years)
   
Aggregate
Intrinsic
Value
 
Outstanding at March 31, 2020
   
318,300
    $
4.08
     
3.0
    $
 
Granted
   
130,000
    $
2.35
     
 
     
 
 
Exercised
   
    $
     
 
     
 
 
Forfeited
   
(41,500
)
  $
3.16
     
 
     
 
 
Outstanding at September 30, 2020
   
406,800
    $
3.62
     
4.4
    $
17,950
 
Exercisable at September 30, 2020
   
281,800
    $
4.19
     
1.9
    $
1,950
 
 
The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price optionees would have received if all options had been exercised on the last business day of the period indicated, based on the Company's closing stock price of
$2.45
and
$2.06
at
September 30, 2020
and
March 31, 2020,
respectively.
 
A summary of the Company's non-vested options for the
six
 months ended
September 30, 2020
is presented below:
 
Nonvested Options
 
Shares
   
Weighted
Average
Grant-Date
Fair Value
 
Nonvested at March 31, 2020
   
37,500
    $
1.52
 
Granted
   
130,000
     
1.20
 
Vested
   
(5,000
)
   
1.27
 
Forfeited
   
(37,500
)
   
1.52
 
Nonvested at September 30, 2020
   
125,000
    $
1.19
 
 
The weighted average grant-date fair value of stock options granted during the
six
months ended
September 30, 2020
was
$6,000.
As of
September 30, 2020,
total unrecognized stock-based compensation expense related to all unvested stock options was
$142,000,
which is expected to be expensed over a weighted average period of
3.6
years.
 
Restricted Stock
 
Grants of fully vested restricted stock issued during the
first
six
months of fiscal year
2021
to Non-Employee Directors was
66,385
shares. Compensation expense recognized for these grants issued under the
2014
Directors Plan was
$158,000.
 
Restricted Stock Units (“RSUs”)
 
 
RSUs are service-based awards granted to eligible employees under the
2016
Plan. Compensation expense recognized for RSUs issued under the
2016
Plan was
$7,000
and
$14,000
for the
three
months ended
September 30, 2020
and
2019,
respectively. Compensation expense recognized for RSUs issued under the
2016
Plan was
$12,000
and
$37,000
for the
six
months ended
September 30, 2020
and
2019,
respectively. In the
first
six
months of fiscal year
2020,
compensation expense included
$6,000
related to a settlement agreement with a former executive.
 
The following table summarizes information related to awarded RSUs for the
six
months ended
September 30, 2020:
 
Nonvested Restricted Stock Units
 
Shares
   
Weighted
Average
Grant Price
 
Nonvested restricted stock units at March 31, 2020
   
12,766
    $
3.98
 
Granted
   
28,647
     
2.15
 
Vested
   
(9,135
)
   
3.97
 
Forfeited
   
(3,090
)
   
2.26
 
Nonvested restricted stock units at September 30, 2020
   
29,188
    $
2.37
 
 
As of
September 30, 2020,
total unrecognized stock-based compensation expense related to unvested restricted stock units was
$59,000,
which is expected to be expensed over a weighted average period of
2.4
years.
 
Common Stock
 
 
In the
first
six
months of fiscal year
2020,
the Company recorded
$205,000
in compensation expense related to a settlement agreement with a former executive.